Intermountain studies genomics
Intermountain Healthcare is launching a long-term prospective study to help physicians and researchers unlock the potential value of genomic data in order to advance precision medicine. The system-wide study, called PRECISE, will enable the serial collection of tissue and blood specimens from healthy individuals, as well as patients with diseases treated at Intermountain Healthcare, and then attempt to link the genomic data to clinical outcomes in the future. “The general collection protocol allows us, in a very broad fashion, to collect leftover specimens from patients that would normally be discarded,” says Bryce Moulton, clinical research director for precision genomics at Intermountain Healthcare. “We have a large electronic health
record, and we have access to clinical data as well, along with these samples.” The tissue storage and analysis for PRECISE will be conducted at Intermountain’s Translational Science Center in St. George, Utah, which leverages the power of next-generation sequencing and state-of-the-art genomics and is capable of sequencing thousands of genomes annually. Recruitment, enrollment and sample collection for the study will take place across the health system’s hospitals and clinics. Intermountain also recently announced it is building a new global DNA database based on electronic health histories from people around the world, which the research community will use to determine who might be at risk for developing genetic diseases.